Literature DB >> 8387438

Effects of genotypes of hepatitis C virus on interferon treatment for chronic type C hepatitis.

N Takada1, S Takase, A Takada.   

Abstract

Interferon is commonly used for treatment of type C hepatitis, but the effects are variable and many factors may be responsible. Hepatitis C virus (HCV) can be classified into 4 types, PT, K1, K2a and K2b. Therefore, the responses to interferon treatment in patients with the different HCV genotypes were analyzed. Twenty-four patients with type C hepatitis were treated with 3 to 10 million units of various types of interferon for more than 8 weeks. HCV-RNA encoding the NS5 region (HCV-NS5) was positive in these 24 patients, 16 of which were classified with the K1 type and 8 with the K2 type of HCV. In all patients except for 2, HCV-NS5 became negative within 3 weeks of treatment without relation to the HCV genotypes. Serum alanine aminotransferase levels were normalized in 7 out of 8 patients in the K2 group and in 4 out of 16 patients in the K1 group at the end of 8 weeks. At the 24th week, ALT levels were normalized in 5 out of 6 patients in the K2 group, and in one out of 9 patients in the K1 group. The percentage of patients exhibiting a good response was significantly higher in the K2 group than in the K1 group at both observation periods. During the post-treatment periods, relapse following complete response was found in 3 patients in the K2 group and in one patient in the K1 group. The final effects of interferon were significantly better in the K2 group than in the K1 group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387438     DOI: 10.1007/bf02779230

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  15 in total

1.  Nucleotide sequences and subtypes of hepatitis C virus genomes.

Authors:  N Enomoto; N Takada; S Takase; A Takada; T Date
Journal:  Gastroenterol Jpn       Date:  1990-06

2.  Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience.

Authors:  O Weiland; R Schvarcz; R Wejstål; G Norkrans; A Frydén
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

3.  One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b.

Authors:  P Ferenci; W Vogel; H Pristautz; J Deimer; H Denk; G Judmaier; K P Maier; G J Krejs; A Gangl
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Typing of hepatitis C virus genomes by restriction fragment length polymorphism.

Authors:  T Nakao; N Enomoto; N Takada; A Takada; T Date
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

7.  A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.

Authors:  G Saracco; F Rosina; M R Torrani Cerenzia; V Lattore; L Chiandussi; V Gallo; R Petrino; A G De Micheli; E Donegani; A Solinas
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

8.  Hepatitis C virus RNA genome in plasma of patients with non-A, non-B hepatitis.

Authors:  N Enomoto; N Takada; S Takase; A Takada; T Date
Journal:  Gastroenterol Jpn       Date:  1991-02

9.  Clinical backgrounds of the patients having different types of hepatitis C virus genomes.

Authors:  N Takada; S Takase; N Enomoto; A Takada; T Date
Journal:  J Hepatol       Date:  1992-01       Impact factor: 25.083

10.  Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region.

Authors:  H Okamoto; S Okada; Y Sugiyama; T Tanaka; Y Sugai; Y Akahane; A Machida; S Mishiro; H Yoshizawa; Y Miyakawa
Journal:  Jpn J Exp Med       Date:  1990-08
View more
  3 in total

Review 1.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

2.  Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.

Authors:  M Tsutsumi; A Takada; M Sawada
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

3.  Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

Authors:  S J Polyak; S McArdle; S L Liu; D G Sullivan; M Chung; W T Hofgärtner; R L Carithers; B J McMahon; J I Mullins; L Corey; D R Gretch
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.